Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Suramin Sodium
Suramin · 1 trial · 1 indication
Adverse Events and Laboratory Results
| Arm | Type | Description |
|---|---|---|
| Suramin 10 mg/kg | EXPERIMENTAL | 50 mg test dose of suramin (upon first administration), then suramin 10 mg/kg (minus 50 mg suramin test dose) in 50 mL of saline administered by IV infusion over 30 minutes was given at Visits 2, 4, and 5. |
| Suramin 20 mg/kg | EXPERIMENTAL | 50 mg test dose of suramin (upon first administration), then suramin 20 mg/kg (minus 50 mg suramin test dose) in 50 mL of saline administered by IV infusion over 30 minutes was given at Visits 2, 4, and 5. |
| Placebo | PLACEBO_COMPARATOR | Test dose of saline placebo, then saline placebo infusion of 50 mL administered over 30 minutes was given at Visits 2, 4, and 5. |
| Name | Type | Description |
|---|---|---|
| Suramin Sodium | DRUG | Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound. |
Inclusion Criteria: * Male children aged 4 - 17 years * Participants with or without treatment interventions for ASD * Participants must have been diagnosed with ASD by Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) * Autism diagnostic observation schedule, version 2 (AD...
Top 2 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 3 | PHASE3 | Xanomeline and trospium chloride, KarX-EC |
| MapLight Therapeutics, Inc. | MPLT | 1 | PHASE2 | ML-004 |